Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 1 crawled time : 12:00 save search
Plus Therapeutics Successfully Treats First Patient in Cohort 8 of ReSPECT-GBM Phase 1/2a Trial
Published: 2023-03-28 (Crawled : 12:00) - globenewswire.com
PSTV | $1.765 -0.57% 6.7K
|
Health Technology
|
| O: 1.97%
H: 0.0%
C: -2.68%
trial therapeutics plus phase 1
Plus Therapeutics Initiates Cohort 3 in Phase 1/Part A of the ReSPECT-LM Trial for Leptomeningeal MetastasesFirst data readout of Phase 1/Part A trial expected second half of 2023
Published: 2023-03-22 (Crawled : 12:00) - biospace.com/
PSTV | $1.765 -0.57% 6.7K
|
Health Technology
|
| O: 3.12%
H: 1.39%
C: 0.0%
expected readout trial therapeutics plus phase 1
Mersana Therapeutics Announces Clinical Hold on XMT-2056 Phase 1 Clinical Trial
Published: 2023-03-13 (Crawled : 12:00) - biospace.com/
MRSN | $3.34 -5.11% -5.39% 1.3M
|
Health Technology
|
| O: -12.12%
H: 13.3%
C: 12.81%
xmt-2056 trial therapeutics clinical hold phase 1
Atea Pharmaceuticals Presents Favorable Drug Interaction Profile of Bemnifosbuvir in Phase 1 Studies at CROI 2023
Published: 2023-02-23 (Crawled : 12:00) - ir.ateapharma.com
AVIR | $3.71 0.0% 270K
|
Health Technology
|
| O: -0.25%
H: 1.01%
C: -2.76%
pharmaceuticals drug bemnifosbuvir favorable phase 1
Affimed Announces Approval of Clinical Trial Application in France for a Phase 1 Study of AFM28 in Relapsed/Refractory Acute Myeloid Leukemia
Published: 2022-12-22 (Crawled : 12:00) - globenewswire.com
AFMD | $5.1 -2.49% -2.55% 90K
|
Health Technology
|
| O: 0.0%
H: 1.68%
C: -1.68%
afm28 application leukemia trial approval study acute myeloid leukemia phase 1
BioNTech Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163
Published: 2022-12-21 (Crawled : 12:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 6.05%
H: 2.65%
C: 0.66%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 2.63%
H: 0.0%
C: 0.0%
BNTX | $86.19 -0.24% -0.24% 580K
|
Health Technology
|
| O: -0.06%
H: 3.49%
C: 3.22%
bnt163 candidate vaccine trial phase 1
BioLineRx Announces Results from Phase 1/2a Study of Investigational Anti-Tumor Vaccine AGI-134 in Metastatic Solid Tumors
Published: 2022-12-20 (Crawled : 12:00) - ir.biolinerx.com
BLRX | $0.6411 3.17% 3.07% 310K
|
Health Technology
|
| O: 1.5%
H: 0.0%
C: -5.43%
agi-134 vaccine tumors results study phase 1
Sempra Infrastructure Announces Sale and Purchase Agreement with INEOS for Port Arthur LNG Phase 1
Published: 2022-12-01 (Crawled : 12:00) - prnewswire.com
SRE | News | $68.44 0.74% 0.0% 3.4M
|
Utilities
|
| O: 0.49%
H: 0.74%
C: 0.13%
COP | News M | $127.81 -0.41% -0.47% 3.6M
|
Energy Minerals
|
| O: 0.94%
H: 0.56%
C: -1.29%
agreement phase 1
Immuneering Announces First Patient Dosed in its Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations
Published: 2022-11-28 (Crawled : 12:00) - globenewswire.com
IMRX | $1.77 -4.84% -5.08% 180K
|
|
| O: 1.67%
H: 1.95%
C: -0.75%
trial tumors phase 1
Algernon Pharmaceuticals Screens First Subject in Phase 1 DMT Human Stroke Study
Published: 2022-11-16 (Crawled : 12:00) - globenewswire.com
AGNPF | $0.0672 178.69% 100
|
Health Technology
|
| O: 4.59%
H: 0.39%
C: -6.69%
pharmaceuticals stroke study phase 1
Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)
Published: 2022-11-14 (Crawled : 12:00) - globenewswire.com
VRDN | $15.17 0.6% 0.59% 580K
|
Health Care and Social Assistan...
|
| O: -2.49%
H: 6.5%
C: 1.6%
vrdn-001 ongoing thyroid disease eye trial positive phase 1
CureVac veröffentlicht vorläufige Daten der Phase 1-Erweiterungsstudie mit Onkologie-Kandidaten CV8102
Published: 2022-11-11 (Crawled : 12:00) - curevac.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: 2.8%
H: 1.16%
C: -2.72%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -4.96%
H: 0.28%
C: -0.72%
CVAC | News | $2.44 -5.06% -5.33% 710K
|
Health Technology
|
| O: 2.72%
H: 7.28%
C: -2.78%
cv8102 phase 1
Trevena Announces Completion of Phase 1 Study for TRV045, Novel S1P Receptor Modulator
Published: 2022-11-09 (Crawled : 12:00) - globenewswire.com
TRVN | $0.3653 -9.13% -10.05% 1.2M
|
Health Technology
|
| O: -3.57%
H: 1.76%
C: -28.18%
trv045 study phase 1
Kura Oncology Reports Preliminary Proof of Mechanism in Phase 1/2 Clinical Trial of Tipifarnib Plus Alpelisib in Head and Neck Squamous Cell Carcinoma
Published: 2022-10-26 (Crawled : 12:00) - globenewswire.com
KURA | $17.66 -1.83% -1.87% 1.7M
|
Health Technology
|
| O: 0.48%
H: 1.51%
C: -4.4%
trial plus cell carcinoma phase 1
Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Study of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients
Published: 2022-10-24 (Crawled : 12:00) - biospace.com/
BPTH | News 0 d | $4.26 31.48% 23.94% 83M
|
Health Technology
|
| O: 1.25%
H: 3.07%
C: -0.61%
bp1002 leukemia study acute myeloid leukemia phase 1
atai Life Sciences Announces Initiation of Phase 1 Proof-of-Concept Clinical Trial for Its Sol-gel Based Direct-to-Brain Drug Delivery Technology
Published: 2022-10-18 (Crawled : 12:00) - biospace.com/
ATAI | $1.91 -3.54% -3.66% 1M
|
Manufacturing
|
| O: 1.7%
H: 1.2%
C: -5.35%
sciences drug life technology trial train phase 1
Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-323, its Novel, Oral L-Protein Inhibitor in Development for the Treatment Respiratory Syncytial Virus
Published: 2022-10-17 (Crawled : 12:00) - biospace.com/
ENTA | $13.23 -5.5% -5.82% 150K
|
Health Technology
|
| O: 0.32%
H: 3.76%
C: 2.8%
edp-323 treatment pharmaceuticals respiratory virus study phase 1
MindMed Collaborators Initiate Phase 1 Comparative PK/PD Trial of R-, S- and Racemic MDMA
Published: 2022-10-04 (Crawled : 12:00) - prnewswire.com
MNMD | $8.92 -6.4% -6.84% 1.6M
|
n/a
|
| O: 1.21%
H: 4.78%
C: 4.48%
trial phase 1
Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with Thalassemia
Published: 2022-09-29 (Crawled : 12:00) - biospace.com/
SLN | $21.98 1.95% 1.91% 120K
|
Health Technology
|
| O: 1.0%
H: 2.38%
C: -0.99%
sln124 therapeutics results study phase 1
Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Company’s First Mutant-Selective RAS(ON) Inhibitor
Published: 2022-09-22 (Crawled : 12:00) - biospace.com/
RVMD S | $35.81 -2.74% -2.82% 1M
|
Health Technology
|
| O: -2.12%
H: 8.84%
C: 7.72%
rmc-6291 trial phase 1
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.